Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Books 15.8 Billion Yen to Boost Regenerative Medicine Manufacturing
December 1, 2025
- Japan Panel Labels Pregabalin for Most Low Back Pain as “Low-Value” Care
December 1, 2025
- Japan Panel Clears KalVista’s HAE Drug, GSK’s Asthma Agent, and More for Approval
November 28, 2025
- Panel Backs Extra Charges for OTC-Like Drugs While Keeping Coverage, but Design Details Still Divisive
November 28, 2025
- As Skepticism Emerges, LDP Health Policy Chief Seeks Stronger R&D Tax Credits
November 28, 2025
- Japan Doles Out Orphan Tags to IgAN Drugs and Lots More
November 28, 2025
- New Govt Casts Pharma as Core Industry, Minister Says at Public-Private Confab
November 27, 2025
- MHLW Floats Prefectural Bodies for Regional Formularies, LLP Copay Hike Gains Traction: LDP-Ishin Talks
November 27, 2025
- MHLW Orders Label Revisions for Anticoagulants, Ondexxya, Tracleer, and More
November 27, 2025
- Lawmakers Hold Cross-Party Study Session on Social Security
November 27, 2025
- US Unveils Up to 85% Price Cuts for IRA Round-2; Astellas’ Xtandi on the List
November 27, 2025
- US FDA Probes Takeda’s Adzynma after Reported Pediatric Death
November 26, 2025
- Celecoxib Faces Unified Pushback Against Rx-to-OTC Switch
November 26, 2025
- LDP, Ishin Start Framing Copay Models for OTC-Like Drugs: Bilateral Talks
November 25, 2025
- Label Updated for Gazyva and Imbruvica: PMDA
November 25, 2025
- Japan Finalizes Economic Package Positioning Pharma as “Core Industry”
November 25, 2025
- Local Legislators Urge Routine HPV Shots for Males as LDP Group Renews Push
November 25, 2025
- Japan to Launch Panel Next Year to Discuss Third-Party Access to Vaccination Database
November 25, 2025
- Japan to Revise Guidance on Standards for Biological Raw Materials
November 25, 2025
- Patient Groups Push Back against Delisting OTC-Like Drugs; Panel Leans Toward Higher Copays
November 21, 2025
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…